Group 1 - The core point of the article is that Zhejiang BoRui Biopharmaceutical Co., Ltd. has submitted an application for an initial public offering (IPO) of overseas listed shares (H shares) to the Hong Kong Stock Exchange, aiming for a listing on January 6, 2026 [1] - BoRui Biopharmaceutical is a leading biopharmaceutical company in China focused on immunotherapy, with integrated capabilities in research, production, and sales [1] - The company aims to provide comprehensive immunotherapy solutions for patients with autoimmune diseases, inflammatory diseases, tumor immunology diseases, and malignancies caused by immune system disorders [1] Group 2 - As of the announcement date, the company holds a 39.62% stake in BoRui Biopharmaceutical [1]

Group 1 - Company Zhejiang Borui Biopharmaceutical Co., Ltd. has submitted an application for an initial public offering (IPO) of overseas listed shares (H shares) to the Hong Kong Stock Exchange on January 6, 2026 [1] - Borui Biopharmaceutical is a leading biopharmaceutical company in China focused on immunotherapy, with integrated capabilities in research, production, and sales [2] - The company has developed a competitive portfolio of immunotherapy products, including the globally first-in-class IL-17A/F inhibitor Beijiele® and the first and only approved targeted CD20 innovative drug Anruixi® [2] Group 2 - Borui Biopharmaceutical has ranked first in the market share of biopharmaceuticals in the field of autoimmune diseases in China for two consecutive years since 2023, based on sales data [2] - The company holds a 39.62% stake in Borui Biopharmaceutical as of the date of the announcement [2]

证券代码：600267 证券简称：海正药业 公告编号：临 2026-04 号 浙江海正药业股份有限公司 博锐生物是国内领先的聚焦免疫疗法的生物制药公司，具备研产销综合一体 化能力。自成立以来，博锐生物始终致力于为自身免疫类疾病、炎症类疾病、肿 瘤免疫类疾病以及免疫系统失调导致的恶性肿瘤类疾病的患者提供全面的免疫 治疗方案。博锐生物已经建立了具有竞争力的免疫产品组合：包括截至目前全球 同类首创、同适应症疗效更优的IL-17A/F抑制剂倍捷乐®（比奇珠单抗），中国 首款且唯一获批靶向CD20的一类创新药安瑞昔®（泽贝妥单抗）等八款已商业化 产品，BR2251（一款拥有差异化作用机制，具有同类首创潜力的在研痛风药物）， 以及基于两大下一代ADC技术平台孵化的多款在研创新ADC管线。根据弗若斯 特沙利文的统计，在涉足自身免疫疾病领域的中国医药企业中，博锐生物按销售 额统计已自2023年起连续两年排名生物制剂市场份额第一。截至本公告披露日， 公司持有博锐生物39.62%的股份。 博锐生物本次递交的申请资料系按照香港证券及期货事务监察委员会及香 港联交所的要求编制和刊发，为草拟版本，其所载资料可能会适时作出更新和变 动。 ...

人民财讯1月6日电，海正药业（600267）1月6日公告，公司从参股子公司浙江博锐生物制药股份有限公 司(简称"博锐生物")处获悉，博锐生物已于2026年1月6日向香港联交所递交了首次公开发行境外上市股 份(H股)并在香港联交所主板上市的申请，并于同日在香港联交所网站刊登了本次发行的申请资料。截 至本公告披露日，公司持有博锐生物39.62%的股份。 ...

Core Viewpoint - Haizheng Pharmaceutical (600267.SH) announced that its associate company, Zhejiang Borui Biopharmaceutical Co., Ltd., has submitted an application for an initial public offering (IPO) of overseas listed shares (H-shares) to the Hong Kong Stock Exchange, with the application materials published on the exchange's website [1] Group 1 - Borui Biopharmaceutical is a leading biopharmaceutical company in China focused on immunotherapy [1] - Haizheng Pharmaceutical holds a 39.62% stake in Borui Biopharmaceutical [1] - The issuance by Borui Biopharmaceutical is subject to approval, authorization, or filing by relevant regulatory agencies and stock exchanges, indicating uncertainty [1]

证券代码：600267 证券简称：海正药业 公告编号：临 2026-03 号 浙江海正药业股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、 会议召开和出席情况 (一) 股东会召开的时间：2026 年 1 月 5 日 (二) 股东会召开的地点：浙江海正药业股份有限公司会议室（台州市椒 江区外沙路 46 号） (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情 况： | 1、出席会议的股东和代理人人数 | 432 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 481,150,965 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 41.3978 | | 份总数的比例（%） | | 注：截止本次股东会股权登记日，公司总股本为 1,198,848,196 股，其中公司回购专用 账户的股份数量为 36,586,700 股，该等回购的股份不享有表决权，故本次股东会享有表决权 的股份总数为 1,162,261,4 ...

北京康达（杭州）律师事务所 BEIJING KANGDA（HANGZHOU）LAW FIRM 二〇二六年一月 北京康达（杭州）律师事务所 海正药业 2026 年第一次临时股东会法律意见书 北京康达（杭州）律师事务所 关于浙江海正药业股份有限公司 2026 年第一次临时股东会的法律意见书 杭州市上城区西子国际中心 2 号楼 1501-1503 室 邮编：310020 电话/Tel.:0571-85779929 传真/Fax:0571-85779955 网址/Website:www.kangdalawyers.com 北京 西安 深圳 海口 上海 广州 杭州 沈阳 南京 天津 菏泽 成都 苏州 呼和浩特 香港 武汉 郑州 长沙 厦门 重庆 合肥 宁波 济南 北京康达（杭州）律师事务所 关于浙江海正药业股份有限公司 2026 年第一次临时股东会的 法 律 意 见 书 康达(杭州)股会字【2026】第 0002 号 康达(杭州)股会字【2026】第 0002 号 致：浙江海正药业股份有限公司 北京康达（杭州）律师事务所（下称"本所"）接受浙江海正药业股份有限 公司（下称"海正药业"或"公司"）委托，指派本所律师出席公 ...

Policy Developments - The State Council approved the revised draft of the Drug Administration Law Implementation Regulations, emphasizing the importance of timely revisions to drug management laws for ensuring public safety and promoting the healthy development of the pharmaceutical industry [1] Industry Initiatives - Hainan Province aims to develop over six distinctive traditional Chinese medicine health tourism routes by the end of 2028, with a target of cultivating over 1 million mu of medicinal herb planting and breeding areas, and achieving a 15% growth in the overall output value of traditional Chinese medicine [2] Drug and Medical Device Approvals - Xingqi Eye Medicine announced the approval of its atropine sulfate eye drops for children aged 6 to 12, with new product specifications added [1] Capital Market Activities - Sinovac Biotech has repurchased approximately 1.32 million shares, accounting for 0.66% of its total share capital, with a total expenditure of approximately RMB 49.24 million [3] - Dongcheng Pharmaceutical plans to repurchase shares worth between RMB 100 million and RMB 200 million for employee stock ownership plans, with a maximum repurchase price of RMB 18.00 per share [4] - Haizheng Pharmaceutical's major shareholder intends to transfer 6.06% of the company's shares through a public solicitation, pending approval from relevant authorities [5] Strategic Collaborations - Sinopharm Holdings and Betta Pharmaceuticals have signed a strategic cooperation agreement to enhance collaboration and create a new efficient pharmaceutical supply chain ecosystem [6] Personnel Changes - The independent director of Nanxin Pharmaceutical, Shen Yunqiao, has resigned for personal reasons, and will continue to fulfill his duties until a new independent director is elected [7]

Investment Agreements - Longpan Technology plans to invest 2 billion yuan to establish a high-performance lithium battery cathode material project [2] - Yanjing Co. intends to acquire control of high-frequency carrier board manufacturer Yongqiang Technology, with stock suspension [2] - Zhongjian Technology has approved a project for the collaborative development of intelligent robots [2] - Mengwang Technology signed a cooperation agreement worth 60 million yuan with Shenzhou Liuhe for the R&D and production of heavy-lift drones [3] - Jiu Ding New Materials plans to invest 246 million yuan to build a large-scale wind turbine blade production line [4] - Jincai Hulin intends to acquire 51% of Wuxi Sanli for 63.43 million yuan [5] - Changyuan Power plans to invest in a 100MW wind farm project in Hubei Province with a total investment of 562 million yuan [7] - Shengyang Co. plans to acquire 51% of Shenzhen Daren High-Tech for 74.47 million yuan [8] Shareholding Changes - *ST Zhongzhuang announced a change in actual control to Long Jisheng due to the execution of a restructuring plan [9] - Hunan Baiyin's major shareholder reduced its stake to below 5% [10] Stock Buybacks - Century Huatong plans to repurchase shares worth between 300 million and 600 million yuan [11] - Dongcheng Pharmaceutical intends to repurchase shares for 100 million to 200 million yuan [12] - Ningde Times has repurchased a total of 15.99 million A-shares for 4.386 billion yuan [13] Business Operations and Performance - Bailong Oriental expects a net profit increase of 46.34% to 70.73% in 2025 [13] - Longjian Co. anticipates a net profit of 405 million yuan in 2025, a decrease of 2.05% [13] - BYD reported cumulative sales of 4.602 million new energy vehicles in 2025, a 7.73% increase year-on-year [14] Financing and Capital Increases - Zhenhua Co. plans to issue convertible bonds to raise no more than 878 million yuan for projects [15] - Huashu Holdings intends to raise up to 600 million yuan through a private placement to Hongtai Group [15] Other Developments - Xinxing Chemical has resumed production of biomass cellulose filament products after equipment upgrades [24] - Guoguang Electric announced the resumption of the general manager's duties after the lifting of restrictions [25]

（记者 曾健辉） 每经AI快讯，海正药业1月4日晚间发布公告称，截至2025年12月底，公司已累计回购股份约722万股， 占公司总股本的比例为0.6%，购买的最高价为10.55元/股、最低价为8.92元/股，已支付的总金额约为 6799万元。 每经头条（nbdtoutiao）——AI泡沫破灭？美股下跌20%？量子计算颠覆加密货币？金价涨破1万美元？ 2026年华尔街和科技圈十大预测来了 ...